×

FDA: Risk of Endo's opioid painkiller outweigh benefits

4:02 PM ET Tue, 14 March 2017

Shares of Endo fall after an FDA panel votes risks of the company's opioid painkiller outweigh the benefits. CNBC's Meg Tirrell reports.